Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Background: This study aims to evaluate the correlation between survival and chronic graft versus host disease (GvHD) occurrence utilising short tandem repeat polymerase chain reaction (PCR) chimerism analysis.

Subjects and Approaches: Every patient who had allo-HSCT between 2005 and 2013 was included in the retrospective cohort. Review of the data collected by day +100 about the prevalence of chronic GvHD and survival. On days 15, 30, and 60, respectively, polymerase chain reaction of short tandem repeats was used to assess chimerism in whole blood, T-cell, and PMN cells (STR).

Conclusion:The ability to take early action to avoid difficulties is made possible by doing continuous study of chimerism.

Keywords: Chronic GvHD, hematopoietic stem cell transplant, chimerism, and polymerase chain reaction

Researchers are looking for novel medical treatments due to the rise of cancer sufferers. Numerous benign and malignant hematologic illnesses are currently treated with hematopoietic stem cell transplantation (HSCT), which is a curative procedure. 1-\s3 HSCT plays a significant role in the treatment of cancer, yet experts are still debating its drawbacks and risks.

4 A major HSCT consequence is graft-versus-host disease (GvHD). Its prevalence has been estimated to be 20–50%. Following the discovery of allo-antigens in the patient's cells, 5-8 T lymphocytes from the donor tissue transform into subgroups of T helper cells, resulting in tissue destruction and GvHD symptoms through tissue invasion and cytokine release.9-11 Cytokine production and release play a key role in the development and severity of GvHD.[12,13] Prolonged A condition known as GvHD may develop 50 to 400 days following transplantation. [14,15] Previous acute GvHD is the main risk factor for chronic GvHD. 16 Stem cell transplantation increases survival rate in patients with harmful illness and expanded number of endure patients with unique clinical issues, for example, constant GvHD for quite a while or long haul persistent GvHD.17 GvHD is a significant boundary to effective HSCT. Despite the fact that GvHD lessens illness repeat and increment sickness free

endurance, it might improve probability of death that are irrelevant to repeat since it adds to organ harm and weakness of the patient to hazardous contaminations.[18] Besides, effective transplantation of hematopoietic stem cells which prompts a drawn out contributor inferred hematopoiesis can be compelling in long haul infection free survival.19 Customary observing of patients after HSCT is vital for relocate assessment.20 One of the primary objectives of posttransplant follow-up is to foresee negative results of transplantation including infection repeat, dismissal and GvHD to apply the preventive medicines, really. Chimerism which is known as consistent presence of giver cells in the transfer beneficiary (have) is one of the anticipated outcomes of transplantation.[21] The event of chimerism has been demonstrated to be an mark of accomplishment and sturdiness of

transplantation.[22] Additionally, chimerism investigation can be utilized in the conclusion of relocate dismissal and repeat of disease.[23-26] The rising number of contributor cells later transplantation decline chance of infection repeat what's more, its initial finding utilizing chimerism investigation helps in assurance of anticipation and early fundamental treatments.27,28 The first investigations on hematopoietic foundational microorganism transplantation have shown the significance of chimerism. Presently, the most valuable and delicate strategies utilized in chimerism examination are sub-atomic hereditary qualities like polymerase chain response in light of polymorphic smaller than expected or icrosatellite markers which can likewise determine exceptionally low quantities of benefactor and beneficiary cells.[29]Since most studies have been done on intense GvHD.This study endeavors to investigate the relationship between STR-PCR-based chimerism investigation and event of persistent GvHD as well as endurance in a test of Iranian patients. This study plans to be supportive in assurance of mediations for patients in danger of dismissal, repeat andcreating cGvHD.

Patients with allo-HSCT alluded to HematologyOncology and Immature microorganism Exploration Center, Tehran,Iran, in 2005-2013 were remembered for the review study. The incorporation standards were patients who got allo-HSCT in 2005 to 2013 what's more, patients with complete clinical records or the likelihood of fulfillment by a due date. Patients with inadequate clinical records or powerlessness to complete data were avoided from the study. For gathering information, an agenda was created in light old enough, sex, chimerism, intense GvHD, constant GvHD, endurance and repeat. Patients were analyzed and their clinical and paraclinical information

were gathered during routine facility visits following transplantation. In this review study, information from allo-HSCT beneficiaries were researched taking into account the occurrence of intense GvHD, ongoing GvHD, repeat and endurance. In this review,chimerism was separated into two classes:complete chimerism (over 95% of hematopoietic cells post-relocate are of giver beginning) and blended chimerism (between 5%-95% cells of giver beginning in hematopoietic tissues). Patients with under 5% giver cells fostered no chimerism. Following 15, 30 and 60 days of transplantation, chimerism was recognized in entirety blood, Lymphocytes and PMN. The connection between aggregate frequency of constant GvHD and chimerism was dissected on days 15, 30 and 60 later transplantation. Molding regimens utilized for different kinds of illness depended on the HSCT convention. GVHD prophylaxis included cyclosporine with momentary methotrexate. The restricted/broad grouping was proposed by the Seattle bunch.14

The technique utilized for chimerism examination in this study was polymerase chain response based shorttandem rehash (STR-PCR) utilizing 12 signs of high separation. In this technique three autosomaltetra nucleotide STR loci with non-covering allele size ranges were all the while intensified. Loci are,D4S2366, D16S539 and TH01. All markers utilized were enhanced under indistinguishable PCR conditions, 200 µM of each dNTP, 20 Pmol of each oligonucleotide groundworks, 10 mM tris HCL (PH=8.3), 50 mM KCL, 2mM MgCL2, 1 unit of Taq DNA polymerase (Fermantas, UK) and 100 ng of format DNA. For visualisation and electrophoresis We employed 6% polyacrylamide gels, and a DNA silver staining technique to see the DNA.

SPSS software was used to examine all of the data. Variables were tested using the T-test and the chi-square test. The STATA, V, 11 statistical package was used to analyse the survival data. To calculate survival, the Kaplan-Meier method, logrank test, and Cox regression model were employed. Statistical significance was assigned to the results (p 0.05). To keep all information private, there is a corresponding code for each patient. Any use or disclosure of personal information must be consistent with the stated aims.

In the current study, 69% of participants had chronic GvHD and 62.1% had acute GvHD. The patients had the highest frequency of limited chronic GvHD. Skin, mucous membranes, and liver are the organs that are most frequently affected by chronic GvHD. 20% of patients experienced relapses, and 40% passed away during the research.In this investigation, patients with complete chimerism (whole blood on day 60, PMN on day 60, and T cell on days 15, 30 and 60) had a considerably greater risk of chronic GvHD. The conclusions of this study are in line with those of a study by Barrios and Rupa-Matysek, who discovered that long-term chimerism or its kinetic assessment is more significant than the absolute value of a single measurement of chimerism. Additionally, constant monitoring of chimerism by the CD3+ subsets of T cells is an effective way to foretell the likelihood of developing GvHD. [33,34] Low T cell chimerism was found to be strongly related with a decreased risk of chronic GvHD, according to a study by Mossallam.

[35].The findings of this investigation are comparable and this study are consistent with those of Sairafi and Pasquet, who found that patients with complete chimerism have a greater frequency of chronic GvHD. [22-24] These findings demonstrated a connection between the prevalence of chronic GvHD and increased patient survival (p=0.0013). Prez et alstudy .'s revealed that individuals with chronic GvHD who underwent nonmyeloablative allogeneic transplantation had a greater survival rate within 24 months than patients without chronic GvHD. 36 Barrios demonstrated that the death rate among leukaemia patients was much lower than that of patients who later had chronic GvHD. [33] The retrospective cohort design of this study had the advantage of allowing for the measurement of exposure and outcome across time. Another element was the checklist created using data from specific patients. The tiny sample size and absence of a clearly defined target audience are just two of the study's many limitations. The results of this survey might not be applicable to other referral centres because the patients were only from one of them greater patient population.

Predicting the occurrence of chronic GvHD, prognosis, and survival using continuous analysis of chimerism after allo-HSCT is helpful. Chimerism analysis also gives you the chance to start taking quick preventative action. Further research is advised to concentrate on particular blood cells to forecast the likelihood of cGvHD recurrence and death in patients receiving allo-HSCT due to the absence of comparable studies and variations in blood components in diverse studies.

1. Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin. 2011; 61(2): 69-90.

2. Thiede C, Bornhäuser M, Oelschlägel U, et al.Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.Leukemia. 2001; 15(2):293-302.

3. Sufliarska S, Minarik G, Horakova J, et al. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin. Neoplasma. 2007;54(5):424-30.

4. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000, 8(1): 33-9.

5. Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008; 41 Suppl 2:S58-64.

6. Passweg J, Zhang MJ, Rocha V, et al. Donor Characteristics Affecting Graft Failure, Graft-versusHost Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. Biol Blood Marrow Transplant. 2011; 17(12):1869-73.

7. Jiang Y, Wan L, Qin Y, et al. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One. 2015; 10(7):e0133671.

8. Cobbold SP, Li XC. Translating Tolerogenic Therapies to the Clinic-Where Do We Stand and What are the Barriers? Front Immunol. 2012; 3:317.

9. Szyska M, Na IK. Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol.2016; 7:118.

10. Spencer GD, Hackman RC, McDonald GB, et al. A prospective study of unexplained nausea and vomiting after marrow transplantation.Transplantation. 1986; 42(6):602-7.

11. Yi T , Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009; 114(14): 3101-12.

12. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graftversus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med.2003; 349(23):2201-10.

13. Remberger M, Ringden O, Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients whodevelop acute GVHD. Bone Marrow Transplant. 1995;15(1):99-104.

14. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204-17.

15. Sullivan KM, Agura E, Anasetti C, et al. Chronic graftversus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991; 28(3):250-9.

16. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLAidentical sibling bone marrow transplantation. Blood. 1990; 75(12):2459-64.

17. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004; 125(4):435-54.

18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in humanrecipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4): 295-304.

19. Barta A, Bátai A, Kelemen E, et al. Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Hum Immunol. 2000; 61(2):101-10.

20. Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 7(9):473-85.

21. Drexler C, Wagner T. Blood group chimerism. CurrOpin Hematol. 2006; 13(6): 484-9.

22. Pasquet L, Joffre O, Santolaria T, et al.Hematopoietic Chimerism and ransplantation Tolerance: A Role for Regulatory T Cells. Front Immunol. 2011; 2:80.

23. Goh RY, Cho SS, Song YJ, et al. Clinical Utility of Chimerism Status Assessed by Lineage-Specific Short Tandem Repeat Analysis: Experience from Four Cases of Allogeneic Stem Cell Transplantation. Korean J Lab Med. 2009; 29(4):277-81.

24. Sairafi D, Remberger M, Uhlin M, et al. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant.2010; 16(12): 1728-37.

25. Goh RY, Kim SH, Han JY. Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablativeallogeneic hematopoietic stem cell transplantation. Korean J Hematol. 2011;46(1):18-23.

26. Lee HC, Saliba RM, Rondon G, et al. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015; 21(11):1948-54.

27. Bader P, Niethammer D, Willasch A, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant 2005; 35(2): 107-19.

28. Petz LD, Yam P, Wallace RB, et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood.1987; 70(5):1331-7.

29. Spyridonidis A, Zeiser R, Wäsch R, et al. Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation. Clinical Transplantation. 2005; 19(3):350-6.

30. Jaksch M, Uzunel M, Remberger M, et al. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II–IV. Clin Transplant. 2005;19(3): 346–9.

31. Alimoghaddam K, Ghaffari H, Foroughi F, et al.Effects of chimerism on graft-versus-host disease,disease recurrence and survival after HLA-identical marrow transplantation in Iran. Arch Iran Med. 2006;9(2):99-103.

32. Balon J, Ha’aburda K, Bieniaszewska M, et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graftversus-host disease. Bone Marrow Transplant. 2005;35(11):1083-8.

33. Barrios M, Jimenez-Velasco A, Roman-Gomez J, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003; 88(7):801-10.

34. Rupa-Matysek J, Lewandowski K, Nowak W, et al.Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2011;43(5):1915-23.

35. Mossallam GI, Kamel AM, Storer B, et al. Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2009; 15(3):352-9.

36. Pérez-Simón JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Br J Haematol. 2003; 121(1):104-8.

Bahram Chahardouli . Chronic GvHD after Hematopoietic Stem Cell Transplantation and STR-PCR Chimerism Analysis Relationship. World Journal Of Hematology And Oncology 2022.